EP2572705A1 - Im Mund dispergierbare Tabletten - Google Patents

Im Mund dispergierbare Tabletten Download PDF

Info

Publication number
EP2572705A1
EP2572705A1 EP20120198042 EP12198042A EP2572705A1 EP 2572705 A1 EP2572705 A1 EP 2572705A1 EP 20120198042 EP20120198042 EP 20120198042 EP 12198042 A EP12198042 A EP 12198042A EP 2572705 A1 EP2572705 A1 EP 2572705A1
Authority
EP
European Patent Office
Prior art keywords
agents
tablet
tablet according
mixture
calcium silicate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP20120198042
Other languages
English (en)
French (fr)
Other versions
EP2572705B1 (de
Inventor
Carmen ÚBEDA PÉREZ
Ignacio DÍEZ MARTÍN
Pablo Pablo Alba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Lesvi SL
Original Assignee
Laboratorios Lesvi SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Lesvi SL filed Critical Laboratorios Lesvi SL
Priority to EP12198042.9A priority Critical patent/EP2572705B1/de
Priority to PL12198042T priority patent/PL2572705T3/pl
Publication of EP2572705A1 publication Critical patent/EP2572705A1/de
Application granted granted Critical
Publication of EP2572705B1 publication Critical patent/EP2572705B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to solid pharmaceutical formulations, in particular it relates to a tablet for oral administration which disintegrates rapidly by the action of saliva in the oral cavity, having also good palatability, friability, mechanical strength properties and employing a conventional manufacturing method to obtain them.
  • orodispersible tablets are defined as non-coated tablets for placing in the mouth which disintegrate quickly before they are swallowed. It also establishes 3 minutes as the time under which they must disintegrate in the disintegration test for tablets and capsules, according to the Ph. Eur. 2.9.1. method.
  • Freeze drying is a process in which a solvent is removed from a drug solution or a drug suspension containing structure-forming excipients.
  • the tablets are characterized by a highly porous network; they quickly absorb water and dissolve, releasing the incorporated drug.
  • the freeze drying process occurs at a low temperature, which eliminates the adverse thermal reactions that may affect drug stability.
  • the freeze-drying process is very expensive and problematic when scaling up.
  • the resulting dosage form is characterised by high friability, low stability at high temperatures and humidity levels, and by showing poor mechanical properties. Moreover, sometimes, special packaging is required.
  • the molding technology can be based in two different processes: the solvent method and the heat method.
  • the solvent molding process involves preparation of a drug solution or suspension that contains a drug and the excipients and evaporating the solvent at ambient pressure and drying.
  • the tablets are formed using a candy floss or shearform matrix, which is composed of saccharides or polysaccarides processed into amorphous floss by the simultaneous action of flash melting and centrifugal forces.
  • the molding technology allows preparing high drug dose tablets and the resulting tablets present a rapid dissolution.
  • molded tablets are subject to erosion and breakage during the handling and opening of the blister pockets.
  • taste masking is an additional requirement with this technology.
  • the conventional process used to prepare fast-dissolving tablets has some advantages, such as being a well established technology, having low manufacturing cost and allowing easy technology transfer (e.g. easy to transfer to different producers).
  • Many strategies for developing tablets with high porosity and suitable mechanical strength have been attempted, including: granulation (wet granulation, dry granulation and mold granulation) followed by compression; and direct compression.
  • fast dissolving tablets are prepared by mixing the granules with a superdisintegrant and other appropriate excipients and compacting to obtain tablets capable of quickly disintegrating in the mouth with a limited amount of saliva.
  • Formulation based on this technology is FlashTab ® to Prographarm which is described in European patent EP 0 548 356 .
  • EP1681048 describes an orally disintegrating tablet of olanzapine prepared with granulation as intermediate step and subsequent compression of the granules.
  • a similar method is also disclosed in DE102005009241 and IP. Com. Journal, 2006 , but they incorporate other active ingredients.
  • EP1488811 refers to orally disintegrating tablets of pravastatin which are obtained by compression moulding of prepared granules.
  • EP1674083 discloses fast disintegrating tablets prepared by first granulating a dispersion containing the ingredients in a spray-drying device, mixing the obtained granules with the active ingredient and magnesium stearate and finally, subjecting the mixture to a tabletting process.
  • Direct compression represents the simplest and most cost-effective tablet-manufacturing technique from a technological point of view.
  • Fast-dissolving tablets can be prepared by using suitable excipients with improved properties.
  • Two known formulations based on this technology are Ziplets ® to Eurand which are described in international patent application WO 99/44580 and DuraSolv ® by Cima described in US patent No. US 6,024,981 .
  • Direct compression based technologies uses suitable excipients with improved properties, most notably superdisintegrants which accelerate the rate of disintegration and hence dissolution. Water soluble excipients and, sometimes, effervescent agents assist in the disintegration process. Addition of insoluble compounds which increase the efficiency of the superdisintegrant: the disintegration time decreases as the amount of hydrophilic insoluble compound increases.
  • Ziplets ® technology is used to obtain taste masking and fast release of watersoluble or water insoluble drugs from microcapsules and granules.
  • the resulting fast-dissolving tablets are obtained by direct compression of mixtures that contain at least one inorganic excipient that is insoluble in water, for example, calcium phosphate, one or more disintegrants, for example, crospovidone and optionally, water soluble excipients.
  • the resulting compositions contain a high percentage of insoluble excipients which leave a high amount of residue in the mouth and jeopardise their palatability.
  • the DuraSolv ® technology is designed to provide stronger tablets without packaging precautions. This technology is based on employment of conventional non-direct compression fillers (such as dextrose, mannitol, sorbitol, lactose and sucrose) in the form of fine particles that quickly dissolve without producing a gritty or sandy sensation in the mouth.
  • conventional non-direct compression fillers such as dextrose, mannitol, sorbitol, lactose and sucrose
  • a formulation based on a dry powdered mixture comprising up to 15% by weight, at least 50% by weight of a diluent and a disintegrant, allows preparing orodispersible tablets by direct compression, with disintegration times very similar to those obtained using more complex techniques.
  • the orodispersible tablets can be disintegrated in the mouth cavity in less than 15 seconds, having also a high mechanical resistance, a low friability and higroscopicity, which involve important advantages with respect to other technologies which require preparing tablets with low resistance and high porosity in order to get short disintegration times.
  • Direct compression provides important advantages over other complex techniques since the active ingredient is not subjected to humidity conditions (water or other solvents) or to high temperatures, conditions which are known to diminish the stability of the oral formulation. In addition, due to its simplicity, it only requires simple machinery leading to a reduction in economic and energetic manufacturing costs.
  • the formulation used in the invention to prepare the orodispersable tablets provides an improved palatability.
  • This technical feature is mainly derived from the incorporation of calcium silicate as excipient which avoids the remaining excipients to agglutinate forming agglomerates which render difficult the dispersion of the tablet in the mouth leading to an unpleasant taste and therefore to a diminished patient compliance.
  • one of the main advantages conferred by this formulation is the possibility of providing tablets with a thickness less than 30% of its major diameter, thus favouring the disintegration in the mouth and also improving the palatability. These features make even easier the administration of active ingredients to patients who have difficulty in swallowing.
  • the amount of calcium silicate is very low, it is also possible to elaborate tablets with a high content of active ingredient, without affecting the final size of the tablet.
  • the present invention relates to an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising:
  • the formulation of the invention can further comprise an effervescent component.
  • a second aspect of the present invention relates to a process for the preparation of a tablet as defined above, which comprises:
  • the present invention is directed to an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% by weight of a diluent, at least a disintegrant, and at least an active ingredient.
  • This solid formulation rapidly disintegrates in the mouth of a patient, also providing a positive organoleptic sensation since non-water soluble components are considerably minimized.
  • the orodispersible tablet is advantageously used in cases where administration without water is necessary, cases of administration to patients who have difficulty in swallowing tablets, or cases of administration to the elderly or to children where there is a fear of blocking the throat if it is unusual tablet form.
  • the orodispersible tablets can be safely administered orally to humans.
  • calcium silicate it is understood a material, natural or synthetic, of formula CaSiO 3 characterized by having a ratio of moles of calcium to moles of silicon, of about 1.0.
  • the calcium silicate used in the present invention is a naturally-occurring mineral, also known as wollastonite, having a CaO/SiO 2 molar ratio ranging from about 0.8 to 1.3.
  • wollastonite also known as wollastonite
  • There exist different crystalline types of wollastonite mineral such as, type 1A (wollastonite), 2M (parawollastonite) and 7M (pseudowollastonite), being type 1A the most prevalent naturally form.
  • These naturally-occurring calcium silicates have a crystalline form and high aspect ratios (above 3:1 and even above 20:1), that provide rigidity and strength.
  • calcium silicate in crystalline form, more preferably ortho-, meta- and alpha- triclinic forms of calcium silicate.
  • crystalline alpha triclinic calcium silicate are those commercially available from Aldrich Chemical, which meets the following specifications: 1.3 m 2 /g surface area, 0.63 g/cc bulk density, 2.90 g/cc true density and ⁇ 1% w/w volatiles, and those from J.M. Huber Inc., Tomita Pharmaceutical Co., and Aldrich Chemical which meets the following specifications: 1.0 to 15 m 2 /g surface area, 0.50 to 0.63 g/cc bulk density, 2.40 to 2.90 g/cc true density and ⁇ 1% w/w volatiles.
  • ortho- and meta- calcium silicate forms are available from Alfa-Aesar and cover the following range of specifications for calcium silicate: 0.98 to 2.5 m 2 /g surface area, 0.49 to 0.90 g/cc bulk density, 2.90 to 3.30 g/cc true density and ⁇ 1% w/w volatiles.
  • the calcium silicate used in the formulation is amorphous and it is generally produced synthetically.
  • the silica source can be selected from naturally occurring pure forms of crystalline silicon dioxide or from synthetic amorphous silicon dioxide.
  • the preferred form of silica is amorphous silicon dioxide, such as precipitated silica, silica gel, fumed silica or colloidal silica.
  • the calcium source may be selected from the group including, silicates, oxides, carbonates, sulfates, hydroxides and salts or mixtures thereof.
  • amorphous calcium silicate examples include those commercially available from Celite Corp (micro-cel C) and J.M. Huber (Hubersorb 250NF and Hubersorb 600NF), which covers the following specifications: 190 to 210 m 2 /g surface area, 0.07 to 0.13 g/cc bulk density, 1.70 to 2.5 g/cc true density and 1% to 14% w/w volatiles.
  • this low aspect ratio (average major axial diameter/average minor axial diameter) of the calcium metasilicate is between about 1:1 to about 2.5:1, preferably from about 1:1 to about 1.5:1, and an water absorption of from about 20 ml/100 g to about 220 ml/100 g, preferably from about 20 ml/100 g to about 100 ml/100 g.
  • the major axis is perpendicular, although not necessarily coplanar, with the minor axis.
  • the calcium metasilicate can be dehydrated (or "calcined").
  • calcium silicate also includes mixtures of the different grades of the calcium silicates mentioned above.
  • the formulation according to the present invention also comprises at least 50% by weight of a diluent.
  • diluents which can be used in the invention include, without limitation, saccharides such as monosaccharides, oligosaccharides or polysaccharides, and/or their oxidised and/or reduced forms; ribose, lactose in its various forms, anhydrous, monohydrate, agglomerated forms or atomised forms; sugar alcohols such as mannitol, maltol, sorbitol, maltitol, xylitol, isomalt and erythritol, cellulose powder, microcrystalline cellulose, silified microcrystalline cellulose or derivatives of cellulose modified chemically, such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose; isomalt, starch, sucrose, pharmaceutically acceptable inorganic compounds such as dibasic calcium phosphate, carbonates of calcium or of magnesium, magnesium oxide, sugar alcohols selected from mann
  • the diluent is an oligosacharide or a sugar alcohol of medium or low solubility selected from maltol, and mannitol and mixtures thereof. More preferably, the diluent is selected from lactose, lactose monohydrate and mannitol.
  • disintegrant it is understood a compound which facilitates the break-up of a tablet when it is placed in aqueous environment. Disintegrants once in contact with water, swell, hydrate, change in volume or form to produce a disruptive force that opposes the efficiency of the binder/s causing the compressed table to break apart. They belong to different morphological classes and posses different functionality properties.
  • Suitable for use in the formulation of the invention include natural starches, such as maize starch and potato starch; directly compressible starches such as starch 1500; modified or pregelatinized starches such as carboxymethylstarches and sodium starch glycolate; natural or chemically-modified cellulose, especially crosslinked sodium carboxymethyl cellulose (croscarmellose sodium) or low substituted hydroxypropyl cellulose; microcrystalline cellulose; gum, especially agar gum, and guar gum; alginic acid or salts thereof; acetates and citrates; sugars (especially lactose, mannitol and sorbitol); aluminum oxide; synthetic polymers such as cross-linked polyvinylpyrrolidones, specially crospovidone.
  • natural starches such as maize starch and potato starch
  • directly compressible starches such as starch 1500
  • modified or pregelatinized starches such as carboxymethylstarches and sodium starch glycolate
  • natural or chemically-modified cellulose especially crosslinked sodium carboxymethyl
  • the disintegrant agent is crospovidone and croscarmellose sodium.
  • the active ingredient can include pharmaceutical ingredients, vitamins, minerals and dietary supplements.
  • the active ingredient is a pharmaceutical ingredient.
  • Pharmaceutical ingredients that may be used include, but are not limited to, gastrointestinal function conditioning agents, anti-inflammatory agents, analgesics, agents for erectile dysfunction therapy, anti-depressants, sedatives, hypnotics, neuroleptics, anti-migraines, antihistaminic agents, for example loratadine, desloratadine, pseudoephedrine, cetirizine and mixture thereof, anti-bacterial agents, antiviral agents, cardiovascular agents, diuretics, anti-hypertensive agents anti-hypolipidemic agents, anti-ulcer agents, antiemetics, anti-asthmatic agents, anti-depressants, anti-thrombotic agents, chemotherapeutic agents, hormones, anti-helmintic agents, anti-diabetic agents, corticosteroids, peptides, proteins, recombinant drugs and mixtures thereof.
  • the pharmaceutical ingredient is selected from the group consisting of loratadine, desloratadine, aripiprazole, olanzapine, risperidone, ondansetron, zolmitriptan, rizatriptan, frovatriptan, eletriptan, almotriptan and salts thereof.
  • the active ingredient is selected from a vitamin, a mineral, a dietary supplement and mixtures thereof.
  • vitamin refers to trace organic substances that are required in the diet.
  • vitamins include, without limitation, thiamine, riboflavin, nicotinic acid, pantothenic acid, pyridoxine, biotin, folic acid, vitamin B 12 , lipoic acid, ascorbic acid, vitamin A, vitamin D, vitamin E and vitamin K.
  • the term vitamin also includes choline, carnitine, and alpha, beta and gamma carotenes.
  • mineral refers to inorganic substances, metals, and the like required in the human diet.
  • minerals include, without limitation, calcium, iron, zinc, selenium, copper, iodine, magnesium, phosphorous, chromium and the like, and mixtures thereof.
  • dietary supplement means a substance which has an appreciable nutritional effect when administered in small amounts.
  • Dietary supplements include, without limitation, ingredients such as pollen, bran, wheat germ, kelp, cod liver oil, ginseng, fish oils, amino acids, proteins and mixtures thereof.
  • dietary supplements may incorporate vitamins and minerals.
  • the amount of active ingredient incorporated in the formulation may be selected according to known principles of pharmacy.
  • An effective amount of pharmaceutical ingredient is specifically contemplated.
  • the term “effective amount” it is understood that the amount or quantity of a drug or pharmaceutically active substance which is sufficient to elicit the required therapeutic response.
  • the term “effective amount” means an amount at least about 10% of the recommended daily dose.
  • the amount of the active ingredient used can vary greatly. Those of ordinary skill in the art will appreciate that the physical characteristics of the active ingredient, the size of the tablet and the requirements of other ingredients will directly influence its limiting content in the formulation. However, generally, the active ingredient does not exceed 30% by weight, preferably from 1 to about 20% by weight, most preferably from 1 to about 15% by weight based on the total weight of the formulation.
  • the authors of the present invention have found that by incorporating an effervescent component in the formulation of the invention an improvement of the palatability of the tablets is obtained, thus providing a pleasant organoleptic sensation. Therefore, the formulation of the present invention can further comprise an effervescent component.
  • Suitable effervescent components that can be used in the formulation of the invention are a mixture comprising a CO 2 donor and an organic acid.
  • Typical CO 2 donors include carbonates and bicarbonates such as sodium bicarbonate, potassium bicarbonate, sodium carbonate and potassium carbonate.
  • Examples of organic acids include, without limitation, citric, malic, tartaric, adipic and fumaric acid.
  • the pharmaceutical composition of the present invention can also include other conventional excipients like surfactants, flavouring agents, lubricants, sweeteners, glidants, antiadherants and mixtures thereof, which affect the elegancy and performancy of the orodispersible pharmaceutical compositions.
  • additional excipients used in said formulation are present in small amounts, e.g. generally less than 10%, preferably 5% of the total mass of the tablet.
  • the lubricant is used herein as an additional excipient that can affect the performance of an orodispersible pharmaceutical composition.
  • Suitable examples of lubricants include but are not limited to talc, sodium benzoate, sodium stearyl fumarate (Pruv), calcium stearate, magnesium stearate, zinc stearate, glyceryl behenate, stearic acid and glyceryl monostearate.
  • Preferred lubricant for the composition of the present invention is sodium stearyl fumarate or magnesium stearate or combination thereof.
  • the lubricant(s) of the present invention are used in an amount of about 0.25 to 5% by weight.
  • Suitable flavouring agents used in the composition of the present invention include but are not limited to strawberry, cherry, orange, peppermint, black currant, banana, raspberry, red fruits, wild berries and caramel flavour.
  • the flavouring agents of the present invention are used in an amount of less than 2% by weight.
  • the sweetener may be selected from the group especially comprising aspartame, potassium acesulfame, sodium saccharinate, neohesperidine dihydrochalcone, sucralose, sucrose, fructose, monoammonium glycyrrhizinate, and mixtures thereof.
  • the sweetener of the present invention is used in an amount of about 1 to 2% by weight.
  • the orally disintegrating tablet of the invention can be rapidly disintegrated in the mouth, having also a high mechanical resistance and low friability.
  • friability refers to an index which provides a measure of the ability of a tablet to withstand both shock and abrasion without crumbling the handling of manufacturing, packaging, shipping and consumer use.
  • the orodispersible tablet of the present invention presents a friability no greater than 1%, preferably no greater than 0.8%.
  • the formulation used in the invention allows preparing orodispersible tablets with a very low thickness, thus increasing the tablet surface and consequently the speed of disintegration.
  • the orodispersible tablet has a thickness less than 30% of its major diameter. This small thickness facilitates the disintegration of the tablet as well as its palatability.
  • the orodispersible tablet of the invention disintegrates in less than 20 seconds, more preferably in less than 15 seconds, even more preferably in less than 10 seconds.
  • the orally disintegrating tablet of the present invention is prepared by direct compression of a dry powdered mixture.
  • direct compression is used in the context of the invention to define a process by which tablets are compressed directly from powder blends of the active ingredient and the excipients (including diluents, fillers, disintegrants and lubricants), which flow uniformly into a die cavity and form a firm compact. No pretreatment of the powder blend by wet or dry granulation procedures is applied. When potent drugs are incorporated in the formulation, these can be sprayed out of solution onto one of the excipients.
  • dry powdered mixture it is understood a mixture of ingredients in powder form, wherein said ingredients have been previously and independently passed through a sieve with mesh size lower than 650 ⁇ m, that guarantees a mean particle size lower than that size, without having been subjected to any granulation process, dissolution or dispersion in a liquid medium.
  • the calcium silicate, the diluent, the disintegrant agent and the active ingredient are homogeneously mixed together in powder form to provide a homogeneous mixture.
  • the mixture is then subjected to direct compression to provide a solid preparation in the form of a tablet.
  • the powder mixture is fed to the die of a tablet press and sufficient pressure is applied to form the solid tablet.
  • Such pressure can vary, and typically ranges about 1.000 - 20.000 N, being particularly preferable 3.000 - 15.000 N.
  • Direct compression is the easiest way of manufacturing tablets and has the great advantage of having a low manufacturing cost. Moreover, it uses conventional equipment, commonly available excipients and a limited number of process steps.
  • the resulting compressed solid preparation possesses a suitable strength and hardness and does not disintegrate during distribution and storage.
  • Orodispersible tablets were made according to the method defined below using the formulation having the ingredients shown in table I: Table I mg % (w/w) 1. Olanzapine 10,00 mg 12,50 % 2. Lactose monohydrate 54,61 mg 68,26 % 3. Hydroxypropylcellulose low-substituted 3,20 mg 4,00 % 4. Crospovidone 2,40 mg 3,00 % 5. Calcium silicate 7,20 mg 9,00 % 6. Aspartame 1,07 mg 1,33 % 7. Banana Flavor 0,16 mg 0,20 % 8. Orange Flavor 0,16 mg 0,20 % 9. Colloidal anhydrous silica 0,40 mg 0,50 % 10. Magnesium stearate 0,80 mg 1,00 % Total 80 mg 100 %
  • the orodispersible tablet was obtained according to the following procedure: a) the components of the formulation were weighted; b) components 4 and 5 were sieved through a screen with a mesh size of 0.5 - 0.6 mm; c) the materials of stage "b" were mixed in a suitable container until a homogeneous mixture was obtained; d) components 1, 2, 3, 6, 7, 8 and 9 were sieved through a screen with a mesh size of 0.5 - 0.6 mm; e) the materials of stage "d” were mixed with the blend obtained in stage "c” in a suitable container until a homogeneous mixture was obtained; f) the component 10 was sieved through a screen with a mesh size of 0.3 - 0.4 mm, it was incorporated into the homogeneous mixture obtained in section "e", and the whole was mixed in a suitable container for approximately 5 minutes g) the mixture powder obtained in stage "f” was compressed in a tabletting machine equipped with suitable punches. Disintegration time 10 sec. Weight 80
  • the disintegration time has been measured according to the following procedure.
  • a filter paper was placed on the bottom of Petri dish and then purified water was poured to achieve a homogeneous humectation.
  • the tablet prepared as defined above was placed on the humectated paper and the complete disintegrating time of the tablet was measured. The test was done six times and the results were averaged.
  • the resistance to crushing of 10 tablets is determined according to the equipment and method described in the Ph. Eur. 2.9.8.
  • the friability of the tablets is performed according to the equipment and method described in the Ph. Eur. 2.9.7.
  • the thickness of a tablet is the distance between the middle point of the two surfaces of the tablet and it is measured with a micrometer.
  • the tablet was prepared according to the procedure described below using the formulation having the ingredients shown in table II: Table II mg % (w/w) 1. Olanzapine 10,00 mg 13,33 % 2. Lactose monohydrate 40,98 mg 54,63 % 3. Hydroxypropylcellulose low-substituted 3,00 mg 4,00 % 4. Crospovidone 3,00 mg 4,00 % 5. Calcium silicate 9,00 mg 12,00 % 6. Aspartame 1,00 mg 1,33 % 7. Calcium carbonate 3,00 mg 4,00 % 8. Tartaric acid 3,75 mg 5,00 % 9. Banana Flavor 0,15 mg 0,20 % 10. Colloidal anhydrous silica 0,38 mg 0,50 % 11. Magnesium stearate 0,75 mg 1,00 % Total 75 mg 100 %
  • the orodispersible table was obtained according to the following procedure: a) components of the formulation were weighted; b) components 4 and 5 were sieved through a screen with a mesh size of 0.5 - 0.6 mm; c) the materials of stage "b" were mixed in a suitable container until a homogeneous mixture has been obtained; d) components 1, 2, 3, 6, 7, 8, 9 and 10 were sieved through a screen with a mesh size of 0.5 - 0.6 mm; e) the materials of stage "d” were mixed with the blend obtained in stage "c” in a suitable container until a homogeneous mixture was obtained; f) the component 11 was sieved through a screen with a mesh size of 0.3 - 0.4 mm, it was incorporated into the homogeneous mixture obtained in section "e", and the whole was mixed in a suitable container for approximately 5 minutes; g) the mixture powder obtained in stage "f” was compressed in a tabletting machine equipped with suitable punches. Disintegration time 11 sec.
  • the tablet was prepared according to the procedure described below using the formulation having the ingredients shown in table III: Table III PR-42 mg % (w/w) 1. Zolmitriptan 2,5 2,77 2. Mannitol granular 73,45 81,61 3. Crospovidone 4,5 5 4. Calcium silicate 6,3 7 5. Aspartame 0,9 1 6. Orange Flavour 0,9 1 7. Strawberry Flavour 0,1 0,11 8. Magnesium Stearate 1,35 1,5 Total 90 100
  • the orodispersible table was obtained according to the following procedure: a) the components of the formulation were weighted; b) component 1, enough amount of 2 to achieve a homogeneous mixture, 3 and 4 were sieved through a screen with a mesh size of 0.5-0.6 mm; c) the materials of stage "b" were then mixed together in a suitable container until a homogeneous mixture was obtained; d) the rest of component 2, and components 5, 6, and 7 were sieved through a screen with a mesh size of 0.5-0.6 mm; e) the materials of stage "d” were mixed together in a suitable container until a homogeneous mixture was obtained; f) component 8 was sieved through a screen with a mesh size of 0.5-0.6 mm, it was incorporated into the homogeneous mixture obtained in section "e", and the whole was mixed in a suitable container for approximately 2 minutes; g) the mixture powder obtained in stage "f” was compress in a tabletting machine equipped with suitable punches. Disintegration time
  • the tablet was prepared according to the procedure described below using the formulation having the ingredients shown in table IV: Table IV mg % (w/w) 1. Ondansetron base 4,00 mg 5,30 % 2. Spry dried mannitol 42,38 mg 56,50 % 3. Microcrystalline cellulose 11,25 mg 15,00 % 4. Sodium croscarmellose 2,25 mg 3,00 % 5. Calcium silicate 6,75 mg 9,00 % 6. Aspartame 1,00 mg 1,30 % 7. Calcium carbonate 3,39 mg 4,52 % 8. Tartaric acid 2,24 mg 2,98 % 9. Peppermint flavour 1,00 mg 1,30 % 10. Magnesium stearate 0,75 mg 1,0 % Total 75 mg 100,00 %
  • the orodispersible table was obtained according to the following procedure: a) the components of the formulation were weighted; b) components 4 and 5 were sieved through a screen with a mesh size of 0.5 - 0.6 mm; c) the materials of stage "b" were mixed in a suitable container until a homogeneous mixture was obtained; d) components 1, 2, 3, 6, 7, 8, 9 and 10 were sieved through a screen with a mesh size of 0.5 - 0.6 mm; e) the materials of stage "d” were mixed with the blend obtained in stage "c” in a suitable container until a homogeneous mixture was obtained; f) the component 10 was sieve through a screen with a mesh size of 0.3 - 0.4 mm, it was incorporated into the homogeneous mixture obtained in section "e", and the whole was mixed in a suitable container for approximately 5 minutes; g) the mixture powder obtained in stage "f” was compressed in a tabletting machine equipped with suitable punches. Disintegration time 9 sec. Weight
  • the tablet was prepared according to the procedure described below using the formulation having the ingredients shown in table V: Table V mg % (w/w) 1. Ondansetron base 4,00 mg 10,00 % 2. Lactose monohydrate 27,95 mg 69,88 % 3. Hydroxypropylcellulose low-substituted 1,60 mg 4,00 % 4. Crospovidone 1,20 mg 3,00 % 5. Calcium silicate 3,60 mg 9,00 % 6. Aspartame 0,53 mg 1,33 % 7. Peppermint flavour 0,52 mg 1,30 % 8. Colloidal anhydrous silica 0,20 mg 0,50 % 9. Magnesium stearate 0,40 mg 1,00 % Total 40 mg 100 %
  • the orodispersible table was obtained according to the following procedure: a) the components of the formulation were weighted; b) components 4 and 5 were sieved through a screen with a mesh size of 0.5 - 0.6 mm; c) the materials of stage "b" were mixed in a suitable container until a homogeneous mixture was obtained; d) components 1, 2, 3, 6, 7 and 8 were sieved through a screen with a mesh size of 0.5 - 0.6 mm; e) the materials of stage "d” were mixed with the blend obtained in stage "c” in a suitable container until a homogeneous mixture was obtained; f) the component 9 was sieved through a screen with a mesh size of 0.3 - 0.4 mm, it was incorporated into the homogeneous mixture obtained in section "e", and the whole was mixed in a suitable container for approximately 5 minutes; g) the mixture powder obtained in stage "f” was compressed in a tabletting machine equipped with suitable punches. Disintegration time 6 sec. Weight 40
  • the tablet was prepared according to the procedure described below using the formulation having the ingredients shown in table VI: Table VI mg % (w/w) 1. Risperidone 2,00 mg 2,50 % 2. Lactose monohydrate 64,3 mg 80,40 % 3. Crospovidone 2,50 mg 3,10 % 4. Calcium silicate 7,50 mg 9,40 % 5. Sodium Cyclamate 2,00 mg 2,50 % 6. Cherry Flavor 0,40 mg 0,50 % 7. Colloidal anhydrous silica 0,40 mg 0,50 % 8. Magnesium stearate 0,90 mg 1,10 % Total 80 mg 100 %

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
EP12198042.9A 2007-10-01 2008-09-30 Im Mund dispergierbare Tabletten Active EP2572705B1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP12198042.9A EP2572705B1 (de) 2007-10-01 2008-09-30 Im Mund dispergierbare Tabletten
PL12198042T PL2572705T3 (pl) 2007-10-01 2008-09-30 Tabletki ulegające rozpadowi w jamie ustnej

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07380265 2007-10-01
US97716607P 2007-10-03 2007-10-03
EP12198042.9A EP2572705B1 (de) 2007-10-01 2008-09-30 Im Mund dispergierbare Tabletten
EP08804908A EP2205213A2 (de) 2007-10-01 2008-09-30 Im mund dispergierbare tabletten

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP08804908A Division EP2205213A2 (de) 2007-10-01 2008-09-30 Im mund dispergierbare tabletten
EP08804908.5 Division 2008-09-30

Publications (2)

Publication Number Publication Date
EP2572705A1 true EP2572705A1 (de) 2013-03-27
EP2572705B1 EP2572705B1 (de) 2017-09-13

Family

ID=38962587

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08804908A Withdrawn EP2205213A2 (de) 2007-10-01 2008-09-30 Im mund dispergierbare tabletten
EP12198042.9A Active EP2572705B1 (de) 2007-10-01 2008-09-30 Im Mund dispergierbare Tabletten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08804908A Withdrawn EP2205213A2 (de) 2007-10-01 2008-09-30 Im mund dispergierbare tabletten

Country Status (11)

Country Link
US (3) US9623010B2 (de)
EP (2) EP2205213A2 (de)
JP (1) JP2010540588A (de)
KR (1) KR101626873B1 (de)
BR (1) BRPI0817927A2 (de)
CA (1) CA2703501C (de)
ES (1) ES2645255T3 (de)
PL (1) PL2572705T3 (de)
PT (1) PT2572705T (de)
WO (1) WO2009043844A2 (de)
ZA (1) ZA201002255B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
ATE498396T1 (de) * 2008-07-21 2011-03-15 Falk Pharma Gmbh Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CN102114014A (zh) * 2009-12-30 2011-07-06 北京德众万全药物技术开发有限公司 一种含有阿莫曲坦的药物组合物
EP2387993B1 (de) * 2010-05-21 2012-11-07 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Im Mund zerfallende Zolmitriptan-Tabletten und Herstellungsverfahren dafür
FR2962331B1 (fr) * 2010-07-06 2020-04-24 Ethypharm Forme pharmaceutique pour lutter contre la soumission chimique, methode la mettant en oeuvre
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
BR112013014827A2 (pt) 2010-12-13 2016-10-04 Antony Wettstein formulações gástricas e colônicas e métodos para produzir e usar as mesmas
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
JP6208931B2 (ja) * 2011-09-07 2017-10-04 三菱商事フードテック株式会社 硬度を高めた口腔内崩壊錠およびその製造方法
WO2013095314A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Pharmaceutical formulations comprising risperidone
WO2013100876A1 (en) * 2011-12-27 2013-07-04 Mahmut Bilgic Risperidone formulations
WO2013172805A1 (en) * 2012-05-14 2013-11-21 Mahmut Bilgic New orodispersible tablet formulations of olanzapine
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
WO2013181694A1 (en) 2012-06-04 2013-12-12 Gaurav Agrawal Compositions and methods for treating crohn's disease and related conditions and infections
WO2014016671A2 (en) 2012-07-27 2014-01-30 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
JP5922851B2 (ja) 2012-11-30 2016-05-24 アキュラ・ファーマシューティカルズ・インコーポレーテッド 活性医薬成分の自己制御放出
JP2016117652A (ja) * 2013-04-16 2016-06-30 株式会社ダイセル 小児への投与に適した速崩壊錠とその簡便な製造方法
JP2016117651A (ja) * 2013-04-16 2016-06-30 株式会社ダイセル 小動物への投与に適した速崩壊錠とその簡便な製造方法
WO2014176632A1 (en) 2013-04-30 2014-11-06 Borody Thomas J Compositions and methods for treating microbiota-related psychotropic conditions and diseases
JP2014218472A (ja) * 2013-05-10 2014-11-20 エルメッド エーザイ株式会社 オランザピン乃至その塩含有錠剤
EP3023109A4 (de) 2013-07-19 2017-01-04 Sanwa Kagaku Kenkyusho Co., Ltd Schmelztablette
EP2845850A1 (de) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidinderivate als Oxytocin/Vasopressin-V1a-Rezeptorantagonisten
WO2015045604A1 (ja) * 2013-09-30 2015-04-02 富士フイルム株式会社 口腔内崩壊錠
WO2015067313A1 (en) * 2013-11-07 2015-05-14 Synthon B.V. Orodispersible pharmaceutical compositions comprising aripiprazole
EP2886107A1 (de) 2013-12-17 2015-06-24 ObsEva S.A. Orale Formulierungen von Pyrrolydinderivaten
SI2886108T2 (sl) 2013-12-23 2023-02-28 Dr. Falk Pharma Gmbh Optimizirana farmacevtska formulacija za zdravljenje vnetnih sprememb požiralnika
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
EP3753921A1 (de) 2014-07-02 2020-12-23 ObsEva S.A. Kristallines (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-on-o-methyloxim und verfahren zur verwendung davon
NZ727876A (en) * 2014-07-11 2018-05-25 Azanta Danmark As Misoprostol dispersible tablet
US20160008310A1 (en) 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
MX2017014488A (es) 2015-05-14 2018-06-11 Crestovo Holdings Llc Composiciones para transplante de la flora fecal y metodos para elaborarlos y utilizarlos y dispositivos para suministrarlos.
JP6856968B2 (ja) 2015-05-22 2021-04-14 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 自閉症スペクトラム障害および関連する症候を治療するための方法
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
EP3352773A4 (de) 2015-09-24 2019-03-27 San Diego State University (SDSU) Foundation DBA San Diego State University Research Foundation Antibakterielle und schützende bakteriophagenformulierungen sowie verfahren zur herstellung und verwendung davon
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
EP3606541A1 (de) 2017-04-05 2020-02-12 Crestovo Holdings LLC Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit (pd) und verwandten erkrankungen
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CA3114423A1 (en) 2018-09-27 2020-04-02 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
KR102084602B1 (ko) * 2018-11-08 2020-03-04 주식회사 서흥 발포성 및 안정성이 향상된 구강 세정용 발포정
CA3116354A1 (en) 2018-11-26 2020-06-04 The Procter & Gamble Company Solid pharmaceutical preparation containing lipoic acid and use thereof
EP3766483A1 (de) * 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispergierbare pulverzusammensetzung mit einem triptan
CN110477378B (zh) * 2019-08-02 2022-11-29 大连医诺生物股份有限公司 含脂溶性成分的口溶型直饮粉及其制备方法
CN112546002B (zh) * 2020-12-07 2022-08-05 北京斯利安药业有限公司 一种生物素口崩片及其制备方法
KR102413426B1 (ko) 2020-12-21 2022-06-29 주식회사 씨엠지제약 나라트립탄을 포함하는 구강용해 필름 제형
WO2024144678A1 (en) * 2022-12-27 2024-07-04 Atatürk Üni̇versi̇tesi̇ Fi̇kri̇ Mülki̇yet Haklari Koordi̇natörlüğü Döner Sermaye İşletmesi̇ Orally disintegrating tablets (odt) formulations for the treatment of flu, common cold and allergic symptoms

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0548356A1 (de) 1991-07-22 1993-06-30 Prographarm Lab Multipartikel-tablette mit schnellauflösbarkeit.
WO1999044580A1 (en) 1998-03-06 1999-09-10 Eurand International S.P.A. Fast disintegrating tablets
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
WO2003045844A1 (en) * 2001-11-28 2003-06-05 J.M. Huber Corporation Calcium metasilicates and methods for making the same
WO2004105680A2 (en) * 2003-05-28 2004-12-09 J. M. Huber Corporation Oral care products comprising calcium metasilicates
EP1488811A1 (de) 2002-03-06 2004-12-22 Kyowa Hakko Kogyo Co., Ltd. Tabletten mit schneller auflösung in der mundhöhle
EP1674083A1 (de) 2003-10-15 2006-06-28 Fuji Chemical Industry Co., Ltd. Tablette mit schneller auflösung in der mundhöhle
EP1681048A1 (de) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Im Munde zerfallende Zusammensetzungen mit Olanzapin oder Donepezil
DE102005009241A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020071864A1 (en) * 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US20030161879A1 (en) * 1999-06-29 2003-08-28 Shinji Ohmori Tablets quickly disintegrating in mouth
US6583722B2 (en) * 2000-12-12 2003-06-24 Kimberly-Clark Worldwide, Inc. Wetness signaling device
ES2199061B1 (es) 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
US20050244347A1 (en) * 2004-04-30 2005-11-03 Mehra Dev K Oral care products comprising calcium phosphates
ES2255429B1 (es) 2004-10-25 2007-08-16 Italfarmaco, S.A. Composiciones farmaceuticas bucodispersables.
JP4944467B2 (ja) * 2005-03-24 2012-05-30 第一三共株式会社 医薬用組成物
CN101203246B (zh) * 2005-03-24 2011-02-02 第一三共株式会社 药物组合物
US20070202163A1 (en) * 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
JP5535616B2 (ja) 2006-03-31 2014-07-02 ルビコン リサーチ プライベート リミテッド 口腔内崩壊錠剤のための直接圧縮性複合材
EP1977734A1 (de) * 2007-04-03 2008-10-08 Royal College of Surgeons in Ireland Verfahren zur Herstellung schnelllöslicher Tabletten
WO2009038145A1 (ja) 2007-09-19 2009-03-26 Asahi Breweries, Ltd. 漢方エキス、生薬エキスあるいは天然物抽出エキスまたはそれらの混合物等の天然物由来物質を含有する顆粒物の製造方法およびその顆粒物から製造する錠剤の製造方法

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0548356A1 (de) 1991-07-22 1993-06-30 Prographarm Lab Multipartikel-tablette mit schnellauflösbarkeit.
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
WO1999044580A1 (en) 1998-03-06 1999-09-10 Eurand International S.P.A. Fast disintegrating tablets
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
WO2003045844A1 (en) * 2001-11-28 2003-06-05 J.M. Huber Corporation Calcium metasilicates and methods for making the same
US6610266B2 (en) 2001-11-28 2003-08-26 Michael C. Withiam Calcium metasilicates and methods for making
EP1488811A1 (de) 2002-03-06 2004-12-22 Kyowa Hakko Kogyo Co., Ltd. Tabletten mit schneller auflösung in der mundhöhle
WO2004105680A2 (en) * 2003-05-28 2004-12-09 J. M. Huber Corporation Oral care products comprising calcium metasilicates
EP1674083A1 (de) 2003-10-15 2006-06-28 Fuji Chemical Industry Co., Ltd. Tablette mit schneller auflösung in der mundhöhle
EP1681048A1 (de) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Im Munde zerfallende Zusammensetzungen mit Olanzapin oder Donepezil
DE102005009241A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"European Pharmacopoeia", June 2004
"Orally disintegrating pharmaceutical composition", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 11 September 2006 (2006-09-11), XP013115762, ISSN: 1533-0001 *
IP. COM. JOURNAL, 2006

Also Published As

Publication number Publication date
ES2645255T3 (es) 2017-12-04
WO2009043844A3 (en) 2009-06-18
PT2572705T (pt) 2017-11-08
EP2205213A2 (de) 2010-07-14
KR20100077187A (ko) 2010-07-07
KR101626873B1 (ko) 2016-06-02
ZA201002255B (en) 2011-12-28
WO2009043844A2 (en) 2009-04-09
JP2010540588A (ja) 2010-12-24
US20160310470A1 (en) 2016-10-27
BRPI0817927A2 (pt) 2015-04-07
CA2703501C (en) 2017-06-13
US20100297031A1 (en) 2010-11-25
US9623010B2 (en) 2017-04-18
US20170157053A1 (en) 2017-06-08
PL2572705T3 (pl) 2018-01-31
CA2703501A1 (en) 2009-04-09
EP2572705B1 (de) 2017-09-13

Similar Documents

Publication Publication Date Title
EP2572705B1 (de) Im Mund dispergierbare Tabletten
US9730896B2 (en) Orally disintegrating tablets and methods of manufacture
RU2189227C2 (ru) Быстро распадающиеся прессованные в формах материалы и способ их получения
Goel et al. Orally disintegrating systems: innovations in formulation and technology
KR20130030306A (ko) 약학 조성물
JPH08301751A (ja) 放出制御型配送システム
EA013211B1 (ru) Быстрораспадающаяся диспергирующаяся во рту лекарственная форма и способ ее приготовления
JP2002255796A (ja) 口腔内速崩壊型錠剤及びその製造方法
EP1944017A2 (de) Schnell in der Mundhöhle zerfallende Tabletten
EP2238974B9 (de) Granulat zur Formulierung von Schmelztabletten
KR20130086159A (ko) 에리스리톨 및 이소말토의 구강분산성 정제
CN105555316B (zh) 通过二阶段的湿式制粒工序制备的崩解性颗粒组合物及含有该组合物的口腔内崩解片剂
Masih et al. Mouth dissolving tablets–a review
Jangid et al. DISPERSIBLE TABLET AS A FORMULATION FOR ORAL DRUG DELIVERY SYSTEM
Agarwal et al. A REVIEW ON: FORMULATION, TECHNOLOGICAL AND BENEFICIAL ASPECTS OF ORAL DISPERSIBLE TABLETS
Singh et al. A REVIEW ON DIFFERENT PHARMACEUTICAL TECHNOLOGYAND DOSAGE FORM USED IN TREATMENT OF DEPRESSION
Chandira et al. Recent aspect of mouth dissolving tablet-an over view

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2205213

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

17P Request for examination filed

Effective date: 20130926

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183629

Country of ref document: HK

17Q First examination report despatched

Effective date: 20150429

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170526

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 2205213

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 927474

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171015

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008052145

Country of ref document: DE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2572705

Country of ref document: PT

Date of ref document: 20171108

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20171024

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2645255

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20171204

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170913

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171213

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 927474

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171213

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180113

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008052145

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

26N No opposition filed

Effective date: 20180614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170913

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1183629

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230921

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20230907

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231002

Year of fee payment: 16

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: NEURAXPHARM PHARMACEUTICALS, S.L.

Effective date: 20240510

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240927

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240927

Year of fee payment: 17

Ref country code: PT

Payment date: 20240905

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240925

Year of fee payment: 17